Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Unravelling the Mechanisms of anti-miR-33-mediated VLDL Lowering

EF 2011-12

Résumé
Heart disease, a leading cause of death worldwide, is particularly prevalent in Canada and the United States, with abnormal lipid levels in the blood being a common cause of heart attacks and stokes. Lipids are shuttled in the circulation in particles called lipoproteins; high concentrations of low and very low density lipoproteins (LDL, VLDL), as well as low concentrations of high density lipoprotein (HDL), are strong and independent risk factors for the development of cardiovascular disease (CVD). A major therapeutic approach for the treatment of CVD is the modulation of lipoprotein metabolism - this is geared towards lowering LDL and VLDL or raising HDL. Despite a continued interest in HDL-raising therapies, the development of suitable pharmacological agents to increase HDL has been challenging. Recently, an important role for microRNA-33 (miR-33) in lipoprotein metabolism was discovered. microRNAs are powerful regulators of gene expression: by silencing numerous gene targets, a single microRNA can preside over an entire cellular pathway. As such, miR-33 negatively regulates many genes involved in HDL formation, and its inhibition raises circulating HDL by an impressive 25-40% and decreases CVD development in mice. When the effect miR-33 inhibition was tested in higher mammals (monkeys), it markedly raised HDL while also unexpectedly lowering VLDL. However, it is unclear how miR-33 modulates plasma VLDL. A full understanding of the cellular and molecular events that impact on lipoprotein metabolism following miR-33 antagonism is required to ensure that there are no adverse effects resulting from the pharmacological inhibition of miR-33. This project will uncover the mechanism of anti-miR-33-mediated VLDL lowering, and deepen our knowledge as to how endogenous miR-33 that is normally expressed upon cholesterol depletion controls a number of events required to maintain normal lipid homeostasis, shedding insight into the regulation of hepatic lipid metabolism.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
242650
Name
Ouimet Mireille I
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Unravelling the Mechanisms of anti-miR-33-mediated VLDL Lowering
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Autophagy; Cardiovascular Disease; Lipid Metabolism; Micrornas
Abstract
Heart disease, a leading cause of death worldwide, is particularly prevalent in Canada and the United States, with abnormal lipid levels in the blood being a common cause of heart attacks and stokes. Lipids are shuttled in the circulation in particles called lipoproteins; high concentrations of low and very low density lipoproteins (LDL, VLDL), as well as low concentrations of high density lipoprotein (HDL), are strong and independent risk factors for the development of cardiovascular disease (CVD). A major therapeutic approach for the treatment of CVD is the modulation of lipoprotein metabolism - this is geared towards lowering LDL and VLDL or raising HDL. Despite a continued interest in HDL-raising therapies, the development of suitable pharmacological agents to increase HDL has been challenging. Recently, an important role for microRNA-33 (miR-33) in lipoprotein metabolism was discovered. microRNAs are powerful regulators of gene expression: by silencing numerous gene targets, a single microRNA can preside over an entire cellular pathway. As such, miR-33 negatively regulates many genes involved in HDL formation, and its inhibition raises circulating HDL by an impressive 25-40% and decreases CVD development in mice. When the effect miR-33 inhibition was tested in higher mammals (monkeys), it markedly raised HDL while also unexpectedly lowering VLDL. However, it is unclear how miR-33 modulates plasma VLDL. A full understanding of the cellular and molecular events that impact on lipoprotein metabolism following miR-33 antagonism is required to ensure that there are no adverse effects resulting from the pharmacological inhibition of miR-33. This project will uncover the mechanism of anti-miR-33-mediated VLDL lowering, and deepen our knowledge as to how endogenous miR-33 that is normally expressed upon cholesterol depletion controls a number of events required to maintain normal lipid homeostasis, shedding insight into the regulation of hepatic lipid metabolism.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ouimet, Mireille I
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~